易急性加重的重度哮喘患者自然杀伤细胞表型失调
本研究通过多参数流式细胞术检测SARP3重度与非重度哮喘患者及健康对照者循环NK细胞受体表达模式，并测定血浆消退素D2（RvD2）和血清淀粉样蛋白A（SAA）水平。结果显示重度哮喘患者存在促炎性SAA过高、促消退性RvD2不足及NK细胞免疫特征改变，与哮喘发病率增加相关，RvD2可对抗SAA介导的NK细胞功能抑制。
要点
- 循环NK细胞活化受体NKp30、NKp46及抑制受体CD161下调与哮喘急性加重易感性和肺功能轨迹相关
- 重度哮喘患者SAA水平升高（中位数8.8 μg·mL-1）、RvD2水平降低（153 pg·mL-1），NK细胞DRV2受体表达较非重度哮喘高2倍
- RvD2可增强NK细胞杀伤活性并部分逆转SAA介导的功能抑制
核心结论
- 重度哮喘存在炎症消退网络紊乱，包括促炎性SAA过量、促消退性RvD2缺乏及NK细胞免疫特征改变，与哮喘发病率增加相关
- RvD2对抗SAA介导的NK细胞效应功能抑制，支持专业促消退介质（SPMs）通过增强细胞特异性消退途径对抗哮喘持续气道炎症的关键机制作用
研究设计与样本
- 采用多参数流式细胞术检测SARP3重度与非重度哮喘受试者及健康对照者循环NK细胞上选定活化和抑制受体（包括RvD2受体DRV2）表达模式
- 测定血浆RvD2和血清淀粉样蛋白A（SAA）水平，体外检测RvD2和SAA对NK细胞杀伤活性的调控作用
主要发现
- 循环NK细胞扩增伴活化受体NKp30和NKp46以及抑制受体CD161下调与哮喘急性加重易感性和纵向肺功能轨迹相关
- 重度哮喘患者循环SAA水平（中位数8.8 μg·mL-1）高于健康个体（2.2 μg·mL-1，p=0.003）
- 重度哮喘血浆RvD2水平（153 pg·mL-1）低于健康对照（208 pg·mL-1，p=0.041），同时NK细胞DRV2受体表达（3973 MFI）较非重度哮喘受试者（1798，p=0.003）高2倍
- 高剂量SAA暴露下调NK细胞触发受体并导致杀伤活性抑制22%（48.9±9.7% vs 对照62.5±9.2%，p=0.001）
- RvD2增强NK细胞杀伤活性（38.1±8.8% vs 33.1±8.3%，p=0.007）并部分逆转SAA介导的抑制（变化5.4±2.7%，p=0.031）
临床怎么用
- 易急性加重的重度哮喘患者循环NK细胞表型改变可作为疾病严重程度和急性加重风险的潜在标志物
- RvD2等专业促消退介质可能成为增强NK细胞功能、对抗持续气道炎症的治疗靶点
以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。
原文
BACKGROUND: Natural killer (NK) cell dysfunction and defective inflammation resolution pathways are associated with chronic airway inflammation in asthma. NK cells are targets for regulation by essential polyunsaturated fatty acid-derived specialized pro-resolving mediators (SPMs), including resolvin D2 (RvD2), to stimulate inflammation resolution.
METHODS: Multiparameter flow cytometry was utilized to examine expression patterns of select activating and inhibitory receptors, including the RvD2 receptor DRV2, on circulating NK cells in SARP3 severe and non-severe asthma subjects and healthy controls. Plasma RvD2 and serum amyloid A (SAA) was measured, and RvD2 and SAA regulation of NK cell cytotoxicity was examined in vitro.
RESULTS: Expansion of circulating NK cells with downregulated activating receptors NKp30 and NKp46 and inhibitory receptor CD161 were linked with exacerbation susceptibility and longitudinal lung function trajectory in asthma. Circulating SAA levels were higher in severe asthma patients (median 8.8 μg·mL-1) than healthy individuals (2.2 μg·mL-1; p=0.003). In contrast, plasma RvD2 levels were lower in severe asthma (153 pg·mL-1 versus 208 pg·mL-1 in health; p=0.041), concomitant with a two-fold higher NK cell DRV2 receptor expression than in non-severe asthma subjects (3973 MFI versus 1798; p=0.003). High-dose SAA exposure downregulated NK cell triggering receptors and resulted in a 22% suppression of cytotoxicity (48.9±9.7% versus 62.5±9.2% in vehicle; p=0.001). In contrast, RvD2 enhanced NK cell cytotoxicity (38.1±8.8% versus 33.1±8.3%; p=0.007) and partially reversed SAA-mediated suppression (5.4±2.7% change; p=0.031).
CONCLUSIONS: These findings identify a perturbed counterregulatory network for inflammation resolution in severe asthma comprised of excess pro-inflammatory SAA, deficient pro-resolving RvD2, and altered NK cell immune signatures that were associated with increased asthma morbidity. The beneficial impact of RvD2 in counteracting SAA-mediated suppression of NK cell effector function supports a pivotal mechanistic role for SPMs to enhance cell-type specific resolution pathways to combat persistent airway inflammation in asthma.
引用
- Duvall, Dorazio, Chiha, et al. Dysregulated NK cell phenotype in exacerbation-prone severe asthma. Eur Respir J. 2026. PMID: 42860276. doi:10.1183/13993003.00317-2026
供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。